Foundation Medicine, Inc. and Memorial Sloan-Kettering Cancer Center on May 02, 2013 announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers. This effort will focus on co-development of a new Foundation Medicine molecular diagnostic product designed to match patients with hematologic cancers (leukemia, lymphoma or myeloma) with the most rational targeted therapies or clinical trials for their cancer. Leaders in hematology from Memorial Sloan-Kettering will help accelerate product development by providing clinical and genomic expertise. This product complements FoundationOne(TM), Foundation Medicine's first product, which offers a similar fully informative genomic profile for solid tumors and likewise provides a concise report to assist physicians in matching patients with the targeted drugs or clinical trials best suited for their unique cancer. FoundationOne was launched in 2012. This new test is being developed using RNA sequencing in addition to DNA sequencing to better enable identification of the unique genes and classes of genomic alterations that are characteristic of hematologic malignancies. Similar to FoundationOne, the new hematologic malignancy test will assist physicians by matching these alterations with targeted treatment options that may be relevant to the patient's genomic profile based on a comprehensive review of published literature. The test will be based on technology, methods and computational algorithms developed by Foundation Medicine, and Foundation Medicine will commercialize the test both in the United States and internationally. Memorial Sloan-Kettering will help accelerate the development and optimization of the product by contributing their clinical and genomic expertise in hematologic malignancies. Foundation Medicine operates a CLIA-certified lab in Cambridge, Mass. and receives clinical patient samples from academic medical centers and community hospitals all over the world. The new test is expected to be commercially available by year-end 2013.

Memorial Sloan-Kettering Cancer Center Presents at 15th Annual Bio CEO & Investor Conference, Feb-11-2013 through Feb-12-2013. Venue: The Waldorf Astoria, 301 Park Avenue, New York, NY 10022, United States. Presentation Date & Speakers: Feb-11-2013, Kenneth Yu, MD, Gastrointestinal Oncology Service, Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes. Feb-12-2013, John F. Gerecitano, MD, PhD, Medical Oncologist & Hematologist.

Memorial Sloan Kettering Presents at BBC CEO New York Conference 2013, Feb-13-2013 01:30 PM. Venue: Apella, 450 East 29th Street, NY 10016, New York, United States. Speakers: Jose Baselga.